Treatments for spasticity and pain in multiple sclerosis: a systematic review
Citations Over TimeTop 10% of 2003 papers
Abstract
Many of the interventions identified are not licensed for the alleviation of pain or spasticity in MS and the lack of evidence relating to their effectiveness may also limit their widespread use. Indeed, forthcoming information relating to the use of cannabinoids in MS may result in there being better evidence of the effectiveness of new treatments than of any of the currently used drugs. It may therefore be of value to carry out double-blind randomised controlled trials of interventions used in current practice, where outcomes could include functional benefit and impact on quality of life. Further research into the development and validation of outcomes measures for pain and spasticity may also be useful, as perhaps would cost-utility studies.
Related Papers
- → Clinical effectiveness of oral treatments for spasticity in multiple sclerosis: a systematic review(2002)83 cited
- → Pharmacological management of muscle spasticity(2022)1 cited
- [Clinical treatment (non surgical) of spasticity in cerebral palsy].(2002)
- → Spasticity and drug therapy(1987)7 cited
- → SPASTICITY — TREATMENT WITH DANTROLENE AND BACLOFEN(1975)